← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.91 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.90 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89 Optimized Temporal Window for Metabolic Boosting Therapy Det (IFNG) — 0.89 TREM2-APOE Axis Dissociation for Selective DAM Activation (TREM2-APOE axis) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.88 APOE-Dependent Autophagy Restoration (MTOR) — 0.88 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.87 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.87 Complement Cascade Inhibition Synaptic Protection (%s) — 0.87 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.87 Optogenetic restoration of hippocampal gamma oscillations vi (PVALB) — 0.87 Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated (PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway) — 0.87 Glymphatic-Mediated Tau Clearance Dysfunction (MAPT) — 0.86 Closed-loop focused ultrasound targeting EC-II PV interneuro (PVALB) — 0.86 TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima (NAMPT) — 0.86 TREM2-Mediated Microglial Dysfunction Disrupts Perivascular (TREM2) — 0.86 Circadian Glymphatic Entrainment via Targeted Orexin Recepto (HCRTR1/HCRTR2) — 0.86 RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P (RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet) — 0.86
Add
|
× MFSD2A-Targeted Lysophosp × Parthenolide reduces toni
MFSD2A (SLC59A1) · neuropharmacology · therapeutic
Composite 0.551
Price $0.56
Evidence For 0
Evidence Against 0
## Mechanistic Overview
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs starts from the claim that modulating MFSD2A (SLC59A1) within the disease context of neuropharmacology can redirect a disease-relevant process. The original description reads: "# MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs ## The Central Hypothesis The proposal that covalent conjugation of specialized pro-resolving mediators (SP
ADORA2A · neuropharmacology · -
Composite 0.659
Price $0.59
Evidence For 0
Evidence Against 0
NF-kB suppression in glia decreases ectonucleotidase and cytokine programs that sustain extracellular adenosine, indirectly reducing ADORA2A pathway output in mood circuits.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammation Unspecified Mechanism neuropharmacology
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary 4/11
dimensions won
MFSD2A-Targeted Lysophosphatidylcholine-
7/11
dimensions won
Parthenolide reduces tonic ADORA2A signa
Radar Chart — 10 Dimensions
Score Breakdown
Dimension MFSD2A-Targeted Lysophosphatid Parthenolide reduces tonic ADO Mechanistic 0.520 0.740 Evidence 0.680 0.580 Novelty 0.850 0.640 Feasibility 0.350 0.740 Impact 0.720 0.660 Druggability 0.450 0.540 Safety 0.550 0.570 Competition 0.700 0.630 Data 0.600 0.680 Reproducible 0.580 0.620 KG Connect 0.077 0.500
Evidence MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN No evidence citations yet
Parthenolide reduces tonic ADORA2A signaling by lowering inf No evidence citations yet
Debate Excerpts MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjug 4 rounds · quality: 0.66
Theorist
# Novel Therapeutic Hypotheses: CNS Penetration of Specialized Pro-Resolving Mediators
---
## Hypothesis 1: LRP1-Targeted Apolipoprotein E-SPM Complexes Exploit Receptor-Mediated Transcytosis
**D...
Skeptic
# Critical Evaluation of CNS Penetration Hypotheses for Specialized Pro-Resolving Mediators
## Hypothesis 1: LRP1-Targeted Apolipoprotein E-SPM Complexes
### Specific Weaknesses
**ApoE-SPM bindin...
Domain Expert
# CNS Penetration of Specialized Pro-Resolving Mediators: Practical Reality Assessment
## Executive Summary
The seven hypotheses represent sophisticated thinking about SPM CNS delivery, but share ...
Synthesizer
# Synthesis Analysis: BBB Penetration of Specialized Pro-Resolving Mediators
## JSON Output
```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H7",
"title": "A...
Parthenolide reduces tonic ADORA2A signaling by lo 4 rounds · quality: 0.66
Theorist Hypothesis 1: Parthenolide does not directly agonize or antagonize ADORA2A; instead it lowers inflammatory adenosine tone in corticostriatal circuits by suppressing NF-kB-driven ectonucleotidase and c...
Skeptic Hypothesis 1 has the best systems logic, but it is one step removed from the phrase "specifically modulate ADORA2A signaling." Reduced inflammation can improve mood behavior without ADORA2A being the ...
Domain Expert The translation path should start with target-validation rather than medicinal chemistry. Use behavioral and molecular assays in stress paradigms with ADORA2A antagonists, agonists, and genetic loss-o...
Synthesizer {"ranked_hypotheses": [{"title": "Parthenolide reduces tonic ADORA2A signaling by lowering inflammatory extracellular adenosine tone", "description": "NF-kB suppression in glia decreases ectonucleotid...
Price History Overlay
Knowledge Graph Comparison
MFSD2A-Targeted Lysophosphatidylcholine-
1 edges
Top Relations promoted: MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs 1
Parthenolide reduces tonic ADORA2A signa
0 edges
Top Node Types
Top Relations